Sorafenib

For research use only.

Catalog No.S7397 Synonyms: BAY 43-9006

237 publications

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Sorafenib has been cited by 237 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NVzobZprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGO5RKSzVyPUCuNFAxODB|MEOg{txO MWjTRW5ITVJ?
MONO-MAC-6 NVzFTlQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXLTWM2OD1yLkCwOFE5KM7:TR?= MULTRW5ITVJ?
ALL-PO NFzL[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7YTWM2OD1yLkCzNVg1KM7:TR?= M{\4OnNCVkeHUh?=
NKM-1 M3TXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjjeIlGUUN3ME2wMlA4PDF4IN88US=> NHfo[HpUSU6JRWK=
CGTH-W-1 NYnoR5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3SUY9rUUN3ME2wMlI2ODJ{IN88US=> MV3TRW5ITVJ?
BB65-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH4OXVKSzVyPUCuOFcxPzNizszN MUPTRW5ITVJ?
NOS-1 NH;LW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwNU[zOkDPxE1? M2jSdHNCVkeHUh?=
SH-4 M4XBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNkW2NVMh|ryP NU\QO|JJW0GQR1XS
HOP-62 NYLrVIQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLidmdKSzVyPUCuPFUxQDhizszN NXf5TmlZW0GQR1XS
HCC2998 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwOEi4NVgh|ryP M2TyTHNCVkeHUh?=
GDM-1 NYXrfHV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHw[4VKSzVyPUCuPVA3QThizszN MX3TRW5ITVJ?
KM12 M33IeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMEKwPVgh|ryP MnzFV2FPT0WU
LB2518-MEL NVv3U5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DNc2lEPTB;MT6yNFgxQSEQvF2= M1f0VHNCVkeHUh?=
NCI-H1436 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonlTWM2OD1zLkKxOlc5KM7:TR?= NVjVVI13W0GQR1XS
EM-2 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwM{W1O|gh|ryP MW\TRW5ITVJ?
LAMA-84 MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PybWlEPTB;MT6zO|Y1QCEQvF2= MYfTRW5ITVJ?
KG-1 NVTB[2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwNEe5N|Uh|ryP NWPoXFNIW0GQR1XS
A388 M4XBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\YTWM2OD1zLkW5NVY2KM7:TR?= NVfyTZZRW0GQR1XS
no-10 NXfXc|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfoTWM2OD1zLk[xO|I3KM7:TR?= NGDaOVlUSU6JRWK=
SF126 NFX3NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PrT2lEPTB;MT62N|gyOiEQvF2= M1rvNnNCVkeHUh?=
MEG-01 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17od2lEPTB;MT64NFk5KM7:TR?= MWjTRW5ITVJ?
A3-KAW MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7YOHhTUUN3ME2xMlg5PDJizszN MWjTRW5ITVJ?
D-247MG M2HXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPQTWM2OD1{LkG0OFgh|ryP NVW0NXlRW0GQR1XS
OVCAR-4 NXjuZ5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXsWYFKSzVyPUKuNlE{QTNizszN MnfnV2FPT0WU
NCI-SNU-1 M3fxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwM{G2NkDPxE1? NUnycFVXW0GQR1XS
NCI-H2171 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG5blJuUUN3ME2yMlM6PzZ2IN88US=> NGDRfFBUSU6JRWK=
SIG-M5 NEXVW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWewUVd{UUN3ME2yMlQzOjR{IN88US=> M2jUcXNCVkeHUh?=
BE-13 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jEfGlEPTB;Mj62PVYxQSEQvF2= NEnkVVVUSU6JRWK=
K052 NVf2TGxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLIdYQ5UUN3ME2yMlc1PjF4IN88US=> NV\seJg{W0GQR1XS
L-540 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor4TWM2OD1{Lke1O|g6KM7:TR?= MlixV2FPT0WU
KMOE-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjsUYl{UUN3ME2yMlgyOzVizszN Mn3oV2FPT0WU
MFH-ino M1rHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpV2lEPTB;Mj65NlE5PSEQvF2= NFP4RWxUSU6JRWK=
HL-60 NXHjVVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n6UWlEPTB;Mz6wOlI6QSEQvF2= MofvV2FPT0WU
HCC2218 NIPLdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTiVVlKSzVyPUOuNVIxODNizszN MV3TRW5ITVJ?
TE-5 NWS5RZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33DTGlEPTB;Mz6xN|E3OiEQvF2= MYDTRW5ITVJ?
MZ1-PC NUW0TmtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHwTWM2OD1|LkS3OVA6KM7:TR?= NWTMTo9SW0GQR1XS
MRK-nu-1 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PsbGlEPTB;Mz62NVQ3QCEQvF2= MWTTRW5ITVJ?
MZ7-mel MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjJW201UUN3ME2zMlY3ODl7IN88US=> M1jZ[3NCVkeHUh?=
BC-1 M{C5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTNwN{SwNkDPxE1? MXjTRW5ITVJ?
ST486 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNwOEO2O|Mh|ryP NYLt[WkyW0GQR1XS
KS-1 NH7Kd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XubWlEPTB;Mz64PFE6QCEQvF2= MnOzV2FPT0WU
SK-NEP-1 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i5RWlEPTB;ND6xOlgyPSEQvF2= NGjp[o9USU6JRWK=
BC-3 M1LnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRwMkOzPVEh|ryP NEDBOlFUSU6JRWK=
NCI-H1581 NETxNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwMki3PVgh|ryP NVTzTWpDW0GQR1XS
MHH-PREB-1 MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4dm9nUUN3ME20MlQxPDh2IN88US=> NE\EWm5USU6JRWK=
NOMO-1 NXX2TG9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwNEi5NFUh|ryP MlrQV2FPT0WU
QIMR-WIL M{[0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwMEeyPVQh|ryP MXrTRW5ITVJ?
SF539 NYH3dWxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT4eJZqUUN3ME21MlE{OjJ5IN88US=> NWXsbYpyW0GQR1XS
TE-12 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;B[mpKSzVyPUWuNlQ6OjlizszN M1XNTHNCVkeHUh?=
NCI-H510A NX;4ZY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXpTWM2OD13LkSxOlg2KM7:TR?= MlnmV2FPT0WU
JAR NUjZVnU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTVwNUC4NlQh|ryP M2jYOXNCVkeHUh?=
no-11 NU\STZpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTQeoVKSzVyPUWuO|M2PjhizszN NFTaWZJUSU6JRWK=
BV-173 NWf4bZZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTVwOUW2PFIh|ryP M13q[XNCVkeHUh?=
SR NVXpb5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTZwMEC2O|gh|ryP MknCV2FPT0WU
MOLT-16 NXe5SJloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULzbm93UUN3ME22MlI2OjZ4IN88US=> M2TNN3NCVkeHUh?=
MZ2-MEL M4Lme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTZwM{G4N|kh|ryP Mo\nV2FPT0WU
SW954 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ETWM2OD14LkS1PFY3KM7:TR?= MWnTRW5ITVJ?
ML-2 M3T1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;ZSmJKSzVyPU[uOVI5PDlizszN NWHPeJROW0GQR1XS
OCI-AML2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XqWWlEPTB;Nj62NVA3OiEQvF2= MmjLV2FPT0WU
SIMA M2HFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn5OlJKSzVyPUeuNFAyODFizszN MmHQV2FPT0WU
DOHH-2 NGTrN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrsTWM2OD15LkC1Olc3KM7:TR?= MnLBV2FPT0WU
697 M1H5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwWGhKSzVyPUeuNFU6QDlizszN M{LHNnNCVkeHUh?=
NB1 M1POdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PjPWlEPTB;Nz60NFQxPyEQvF2= MnfaV2FPT0WU
D-392MG MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELC[|RKSzVyPUeuOlI3PjNizszN MmLoV2FPT0WU
ES8 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq0cXY6UUN3ME23Mlc3PTB|IN88US=> MYnTRW5ITVJ?
RPMI-8226 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\wTGlEPTB;Nz64OFUyOSEQvF2= NIPFVHRUSU6JRWK=
IST-MEL1 NVPUeWJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC1TWM2OD16LkSwNFAzKM7:TR?= MnniV2FPT0WU
NB14 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj6TWM2OD16Lk[zNVM{KM7:TR?= MmexV2FPT0WU
HD-MY-Z NGHNT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRThwNkO3OFYh|ryP MVnTRW5ITVJ?
TE-10 M{DZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHRTWM2OD16Lke2N|U{KM7:TR?= NWL5cZhGW0GQR1XS
LC-1F M3;jWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\hfWlEPTB;OT6xNFg{PCEQvF2= M3LTV3NCVkeHUh?=
OS-RC-2 NIHyOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\zTWM2OD17LkGxNlQ{KM7:TR?= MmOwV2FPT0WU
NCI-SNU-16 NY\4S|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTlwMkGwNlYh|ryP NGjNbm1USU6JRWK=
SHP-77 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTlwN{G2OlIh|ryP NWXPSVZ1W0GQR1XS
A4-Fuk M4\5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULEcpZbUUN3ME25Mlc2PjFizszN NGLlTXpUSU6JRWK=
NB6 M3\wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTlwN{[wNlkh|ryP NYflU2RuW0GQR1XS
JiyoyeP-2003 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LKTmlEPTB;MUCuOFc1PSEQvF2= NVHRd29yW0GQR1XS
DMS-114 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnhTWM2OD1zMD61OFQyKM7:TR?= M1exfnNCVkeHUh?=
NB7 M{TJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETadGVKSzVyPUGwMlc2OjZizszN MWnTRW5ITVJ?
NCI-H747 NGPNelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTSXYFyUUN3ME2xNU4yOjF4IN88US=> MlrGV2FPT0WU
HH M4\B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLZTWM2OD1zMT6zPFc3KM7:TR?= Mo\LV2FPT0WU
EW-18 NF;SU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3uUVhKSzVyPUGxMlkxPDRizszN NYTDbJk4W0GQR1XS
CHP-126 M3rmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S5VGlEPTB;MUGuPVc{QCEQvF2= M2XBbXNCVkeHUh?=
NTERA-S-cl-D1 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzjTWM2OD1zMj6wNlc5KM7:TR?= MX7TRW5ITVJ?
DEL NYH5SmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13pPGlEPTB;MUKuNFk5PSEQvF2= M1zhbHNCVkeHUh?=
LU-139 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TlfGlEPTB;MUKuOVQyOyEQvF2= MXHTRW5ITVJ?
P30-OHK NWrQellWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL2TWM2OD1zMj61OFc6KM7:TR?= NWjCPVR[W0GQR1XS
NCI-H1522 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XXeGlEPTB;MUKuO|Q3KM7:TR?= NWK3WmszW0GQR1XS
NCI-H1299 M3OybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfJW4xKSzVyPUGzMlI6OTFizszN NV\i[pU6W0GQR1XS
UACC-257 NX21bWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrjTWM2OD1zMz61NVI3KM7:TR?= NFLmd2VUSU6JRWK=
Calu-6 NULiVG0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC3TWM2OD1zMz62NFQ3KM7:TR?= MXvTRW5ITVJ?
NCI-H1882 NUjvNm9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LL[WlEPTB;MUOuPFU2PSEQvF2= MUnTRW5ITVJ?
BB30-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zMTmlEPTB;MUSuNFYxQSEQvF2= NEHmcZRUSU6JRWK=
ES1 M2P6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L3c2lEPTB;MUSuNVU2OSEQvF2= MnjZV2FPT0WU
NCI-H1694 M{DlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF2LkS4NVEh|ryP MV3TRW5ITVJ?
IST-SL1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TjNmlEPTB;MUSuPVYyPiEQvF2= NF74O5pUSU6JRWK=
ECC4 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHNdmtKSzVyPUG1MlA2PThizszN MV7TRW5ITVJ?
MDA-MB-134-VI NUnaW4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TrWGlEPTB;MUWuOFE{OSEQvF2= MnT3V2FPT0WU
SCH MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF3LkS3Nlgh|ryP M2\VeXNCVkeHUh?=
SK-N-FI NGKySVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrT[XlOUUN3ME2xOU43PTN2IN88US=> NH\lbJlUSU6JRWK=
HDLM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnsWnRKSzVyPUG2MlA4OTRizszN MUPTRW5ITVJ?
Ramos-2G6-4C10 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrhdYFKSzVyPUG2MlEzQTdizszN MVfTRW5ITVJ?
EW-24 NGPibIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jORmlEPTB;MU[uNVY3OSEQvF2= MVnTRW5ITVJ?
NCI-H2141 M4XHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTXTWM2OD1zNj6xPFkh|ryP NGXxdmhUSU6JRWK=
LC4-1 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF4Lk[xNVkh|ryP Mn\ZV2FPT0WU
HT-144 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljXTWM2OD1zNz6wNFYh|ryP NVK0RnZEW0GQR1XS
SK-MEL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\uZ4dKSzVyPUG3MlAxPzJizszN NWHNe|Y{W0GQR1XS
SCC-15 NIfLbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojUTWM2OD1zNz6xOlM5KM7:TR?= MX\TRW5ITVJ?
C8166 M{LufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF5Lk[4N|Mh|ryP M1TiXHNCVkeHUh?=
GOTO MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO5TnRKSzVyPUG3Mlg{PDRizszN NUjsTXdMW0GQR1XS
COR-L279 NWXCSphQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS4fnNKSzVyPUG4MlE{PjJizszN M2jxeHNCVkeHUh?=
K-562 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPPe2JOUUN3ME2xPE44OTR|IN88US=> NF\XV2xUSU6JRWK=
ES3 NXzveIpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHabotTUUN3ME2xPE45ODRzIN88US=> M4W1XHNCVkeHUh?=
LU-165 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF7LkewNFgh|ryP NWjK[mF2W0GQR1XS
KM-H2 M37FSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjDUpNKSzVyPUKwMlMyQDRizszN M3XxVnNCVkeHUh?=
RL NVTlNGdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJyLkm2PVIh|ryP NFPG[GVUSU6JRWK=
EW-3 NXnx[|ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jJT2lEPTB;MkGuNVg5QSEQvF2= NF;0[GpUSU6JRWK=
A101D M33BXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHlTWM2OD1{MT6zO|UzKM7:TR?= NGW4S|RUSU6JRWK=
HUTU-80 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HN[mlEPTB;MkGuN|k1PiEQvF2= MUjTRW5ITVJ?
NCI-H23 NXTtZWNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHDTWM2OD1{MT6zPVkzKM7:TR?= MYTTRW5ITVJ?
PF-382 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXTVoVKSzVyPUKxMlQ1ODNizszN M4\WbXNCVkeHUh?=
LB373-MEL-D NV\FdYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJzLkW2NVUh|ryP MU\TRW5ITVJ?
TE-8 M1\sW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYryUIh6UUN3ME2yNU43Ozl2IN88US=> NG\zdZZUSU6JRWK=
TE-9 NH7U[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXoTI5RUUN3ME2yNU45PTF|IN88US=> MVfTRW5ITVJ?
Daudi MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJzLkmzNFQh|ryP MkDmV2FPT0WU
D-542MG NYTzelNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OxeGlEPTB;MkKuNFI2PiEQvF2= Mn7FV2FPT0WU
U-698-M M2OyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H2WmlEPTB;MkKuOFYxOyEQvF2= M4fXXnNCVkeHUh?=
ES6 M1nYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XjbGlEPTB;MkKuO|M3PiEQvF2= NXTxVWptW0GQR1XS
DU-4475 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ|Lki4PVch|ryP M3LkTHNCVkeHUh?=
ECC12 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ2LkK4NFMh|ryP MVzTRW5ITVJ?
C2BBe1 M1yze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfOdG1KSzVyPUK0MlMzOzlizszN NIPVN|JUSU6JRWK=
IST-SL2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nhVGlEPTB;MkSuOFM3OiEQvF2= M2jOSHNCVkeHUh?=
DJM-1 M1LJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvP[YhKSzVyPUK0MlUzOjFizszN MXHTRW5ITVJ?
DMS-153 NGrqZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LOVGlEPTB;MkSuPFYyPCEQvF2= MmntV2FPT0WU
NB13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml20TWM2OD1{NT6wNlY2KM7:TR?= NFzXbnhUSU6JRWK=
SK-N-DZ NVm2bpN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HFcmlEPTB;Mk[uN|QyPCEQvF2= MlrTV2FPT0WU
COR-L88 NYO3[WNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\HdWVKSzVyPUK2MlU4QTZizszN M{TEW3NCVkeHUh?=
LU-65 NYTxTolmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ4Lki1N|Uh|ryP MnrVV2FPT0WU
TGBC1TKB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L2cmlEPTB;Mk[uPVgzQCEQvF2= MV7TRW5ITVJ?
THP-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJ5LkKxOFEh|ryP M1:5cnNCVkeHUh?=
ONS-76 M4fHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7aTWM2OD1{Nz6zN|Ih|ryP MVjTRW5ITVJ?
LC-2-ad NXKwN4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ5Lk[yN|Eh|ryP MmKyV2FPT0WU
EW-13 NIH1cI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPleZBKSzVyPUK5MlE4PDZizszN MmHVV2FPT0WU
MS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jWd2lEPTB;M{CuO|I4QCEQvF2= MX3TRW5ITVJ?
NCI-H2227 NIGwPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjJPWJKSzVyPUOwMlk5ODZizszN NGPEOWtUSU6JRWK=
LXF-289 NUmyNlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HTWWlEPTB;M{GuOFQ6OiEQvF2= NEjuU2xUSU6JRWK=
MC116 M33F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\kcIlKSzVyPUOyMlA5OjZizszN NUnUe5RGW0GQR1XS
EVSA-T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3joVGlEPTB;M{KuNlU5PSEQvF2= MXHTRW5ITVJ?
CTB-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTN|LkGxNFEh|ryP M3fqTHNCVkeHUh?=
COLO-320-HSR Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[zW3BKSzVyPUOzMlE3ODNizszN NGHvSXBUSU6JRWK=
NCI-H2196 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP5eJFyUUN3ME2zN{4zPTV5IN88US=> NF;wV|FUSU6JRWK=
LB2241-RCC MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTN|LkOxN|Uh|ryP NXTO[Zo2W0GQR1XS
LS-513 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHRTWM2OD1|Mz64OlM5KM7:TR?= MljwV2FPT0WU
LP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu2NYh1UUN3ME2zN{46QTV4IN88US=> M2P6XnNCVkeHUh?=
A253 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPjTHVFUUN3ME2zOE4zOjl4IN88US=> NWnqR5FLW0GQR1XS
SK-MM-2 NV64b4JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L3S2lEPTB;M{SuPVQ2OSEQvF2= NV61XoJLW0GQR1XS
NCI-H1963 NV;iVYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWxSYtKSzVyPUO1MlMxPzJizszN Mn3lV2FPT0WU
MMAC-SF NIrsUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[yUGlEPTB;M{WuPFc5PSEQvF2= MYDTRW5ITVJ?
LB831-BLC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjLTWM2OD1|Nj6wOlU1KM7:TR?= MmnqV2FPT0WU
WSU-NHL NY\hNZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN4LkG2OEDPxE1? NV\LPZVCW0GQR1XS
CESS MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXXfm1FUUN3ME2zOk4zQDR6IN88US=> MVPTRW5ITVJ?
NEC8 NYnWXplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTaTWM2OD1|Nj61PFM2KM7:TR?= MnLRV2FPT0WU
KNS-42 M4nTRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzR[nBKSzVyPUO3MlEzOzdizszN NV3GO|c2W0GQR1XS
MHH-CALL-2 NIDkRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnaSWUzUUN3ME2zO{4yQDJzIN88US=> NEfqW2pUSU6JRWK=
K5 M3TmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX1TWM2OD1|OD60N{DPxE1? M{Xs[HNCVkeHUh?=
CP66-MEL MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN7LkC3N|Mh|ryP MVjTRW5ITVJ?
OPM-2 NYDjSWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD4TWM2OD1|OT64OFMzKM7:TR?= MkPyV2FPT0WU
IST-MES1 M3;E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjlb5RKSzVyPUSwMlMxQTZizszN Mlv6V2FPT0WU
EC-GI-10 NUXrdHNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITwSXFKSzVyPUSxMlU5ODVizszN NHv1PIVUSU6JRWK=
CTV-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPFfHJKSzVyPUSyMlg1ODZizszN M3T1RXNCVkeHUh?=
DG-75 NWLKO4p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR|Lke1PVUh|ryP NHP6VopUSU6JRWK=
KNS-81-FD NGD5SlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jEVmlEPTB;NEWuOFA2QCEQvF2= MoXkV2FPT0WU
NCI-H82 M2\6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjOWFBKSzVyPUS1MlU4PThizszN NYe4PYpmW0GQR1XS
RPMI-8866 M2LJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;FW2lEPTB;NE[uNVg4OyEQvF2= Ml;DV2FPT0WU
ACN NGHwPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TXOmlEPTB;NE[uOFM1KM7:TR?= Mk\hV2FPT0WU
NCI-H1395 NVTDfIRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTSTWM2OD12Nj60O|U3KM7:TR?= M3rHNXNCVkeHUh?=
NCI-H209 NGK4TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\TOpNKSzVyPUS3MlE1ODVizszN NUHXPJpXW0GQR1XS
TGW Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrCTo4zUUN3ME20PU4xPzlzIN88US=> MVPTRW5ITVJ?
NCI-H748 M4i5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\BTWM2OD12OT60O|U{KM7:TR?= NHv1bGZUSU6JRWK=
EKVX NXnVc5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X4XGlEPTB;NEmuOlYzQCEQvF2= M3TiVXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

- Collapse
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 400+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006
Smiles CNC(=O)C1=CC(=CC=N1)OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. January 10 2020 Phase 2
NCT03958669 Recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research November 1 2019 --
NCT03764293 Recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. June 10 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID